11.89

5.03% -0.63

Trevi Therapeutics Inc (TRVI)

Overview News Price History Option Chain Financials Discussions Forecast

Trevi Therapeutics Inc stock is traded at $11.89, with a volume of 1.52M. It is down -5.03% in the last 24 hours and down -10.94% over the past month. Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Previous Close:

$12.52

Open:

$12.58

24h Volume:

1.52M

Relative Volume:

0.84

Market Cap:

$1.52B

Revenue:

Net Income/Loss:

$-29.07M

P/E Ratio:

-41.00

EPS:

-0.29

Net Cash Flow:

$-31.85M

1W Performance:

-7.47%

1M Performance:

-10.94%

6M Performance:

+98.83%

1Y Performance:

+172.71%

1-Day Range:

$11.60

$12.60

1-Week Range:

$11.60

$13.16

52-Week Range:

$3.4715

$14.39

Trevi Therapeutics Inc Stock (TRVI) Company Profile

Name

Trevi Therapeutics Inc

Sector

Healthcare (1131)

Industry

Biotechnology (631)

Phone

203-304-2499

Address

195 CHURCH STREET, NEW HAVEN, CT

Employee

Twitter

@TreviThera

Next Earnings Date

2025-03-18

Latest SEC Filings

TRVI's Discussions on Twitter

Compare TRVI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TRVI Trevi Therapeutics Inc	11.89	1.61B	0	-29.07M	-31.85M	-0.29
VRTX Vertex Pharmaceuticals Inc	452.13	115.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.31	81.12B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	400.17	52.54B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	839.99	51.78B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	177.12	37.12B	447.02M	-1.18B	-906.14M	-6.1812

Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-13-25	Initiated	Leerink Partners	Outperform
Aug-21-25	Initiated	Morgan Stanley	Overweight
Jul-01-25	Initiated	Cantor Fitzgerald	Overweight
May-28-25	Initiated	H.C. Wainwright	Buy
Mar-10-25	Reiterated	Needham	Buy
Mar-10-25	Upgrade	Raymond James	Outperform → Strong Buy
Dec-12-24	Reiterated	H.C. Wainwright	Buy
Sep-09-24	Resumed	Leerink Partners	Outperform
Aug-30-24	Initiated	H.C. Wainwright	Buy
Aug-30-24	Initiated	Raymond James	Outperform
Jun-13-24	Initiated	Rodman & Renshaw	Buy
Apr-12-23	Initiated	B. Riley Securities	Buy
Nov-22-22	Initiated	SVB Leerink	Outperform
Jun-03-19	Initiated	BMO Capital Markets	Outperform
Jun-03-19	Initiated	Needham	Buy
Jun-03-19	Initiated	SVB Leerink	Outperform
Jun-03-19	Initiated	Stifel	Buy

View All

Trevi Therapeutics Inc Stock (TRVI) Latest News

03:08 AM

Trevi Therapeutics (TRVI) targets next phase of growth with leadership change - MSN

Dec 29, 2025

Dec 21, 2025

Trevi Therapeutics (TRVI) Targets Next Phase of Growth with Leadership Change - Finviz

Dec 21, 2025

Flputnam Investment Management Co. Raises Stock Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat

Dec 21, 2025

Dec 20, 2025

Is Trevi Therapeutics Inc. stock cheap at current valuationJuly 2025 PreEarnings & High Yield Equity Trading Tips - Улправда

Dec 20, 2025

Will Trevi Therapeutics Inc. stock rally after Fed decisionsRisk Management & Low Risk Growth Stock Ideas - Улправда

Dec 20, 2025

Dec 19, 2025

Stifel Maintains Trevi Therapeutics (TRVI) Buy Recommendation - Nasdaq

Dec 19, 2025

Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know - MSN

Dec 19, 2025

Trevi Therapeutics stock price target raised to $18 by Stifel on cough drug potential - Investing.com Canada

Dec 19, 2025

First Week of TRVI February 2026 Options Trading - Nasdaq

Dec 19, 2025

TRVI: Stifel Raises Price Target and Maintains Buy Rating | TRVI Stock News - GuruFocus

Dec 19, 2025

What dividend safety score for Trevi Therapeutics Inc. stockJuly 2025 Analyst Calls & Weekly Top Gainers Trade List - DonanımHaber

Dec 19, 2025

Why Trevi Therapeutics Inc. stock remains on buy listsJuly 2025 Chart Watch & Comprehensive Market Scan Reports - DonanımHaber

Dec 19, 2025

Dec 18, 2025

Can Trevi Therapeutics Inc. stock sustain market leadershipWeekly Profit Recap & Free Community Supported Trade Ideas - Улправда

Dec 18, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of "Buy" from Analysts - MarketBeat

Dec 18, 2025

Dec 11, 2025

Trevi Therapeutics stock hits all-time high of 14.01 USD By Investing.com - Investing.com Nigeria

Dec 11, 2025

Marshall Wace LLP Has $13.55 Million Stock Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat

Dec 11, 2025

Trevi Therapeutics Stock Surges to Record High on Clinical and Strategic Momentum - AD HOC NEWS

Dec 11, 2025

Trevi Therapeutics (NASDAQ:TRVI) Hits New 12-Month HighTime to Buy? - MarketBeat

Dec 11, 2025

Dec 10, 2025

Trevi Therapeutics (NASDAQ:TRVI) Trading 5.7% HigherTime to Buy? - MarketBeat

Dec 10, 2025

Trevi Therapeutics stock hits all-time high of 14.01 USD - Investing.com

Dec 10, 2025

Dec 09, 2025